MAP2K1 and cystic fibrosis: Other non-CF models of infection and inflammation demonstrated complementary findings to our results, supporting the anti-inflammatory therapeutic potential of MEK1/2 inhibitors (Schuh and Pahl, 2009; Shi-Lin et al., 2015; Saint et al., 2016; Smith et al., 2016; Yu et al., 2022).